Paper Details

  1. Home
  2. Paper Details

A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.

Author: , BensonConstance A, BixbyChristian J, DowneyGerald F, GlesbyMarshall J, GulickRoy M, HavlirDiane V, LedermanMichael M, MellorsJohn W, PatelSheran, RinehartAlex R, SnyderSally, VaidaFlorin, WangRui, WantmanMichael

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

A 16-week structured treatment interruption (STI) before optimized ART did not improve virologic response in patients with drug-resistant HIV-1.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in patients with drug-resistant human immunodeficiency virus type 1 (HIV-1) is uncertain. METHODS: AIDS Clinical Trial Group protocol A5086 was a prospective trial of 41 patients with multi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1086/508289

データ提供：米国国立医学図書館（NLM）

Treatment Interruption Before Optimized Antiretroviral Therapy for HIV: A Clinical Trial

HIV continues to be a global health challenge, and researchers are constantly seeking new and effective treatments to combat the virus. This study investigates the role of structured treatment interruption (STI) before optimized antiretroviral therapy (ART) in individuals with drug-resistant HIV. The study aims to determine if a period of treatment interruption would improve the effectiveness of ART in individuals with multiple drug-resistant HIV.

Treatment Interruption Does Not Improve Virological Response in Drug-Resistant HIV

The study's findings suggest that a 16-week STI before optimized ART did not improve virological response in individuals with drug-resistant HIV. In fact, the reemergence of drug-resistant virus was observed in many participants, highlighting the challenges associated with treatment interruption in individuals with highly resistant HIV.

The Importance of Ongoing Research and Personalized Treatment Approaches

This study underscores the importance of ongoing research to find new and more effective treatments for drug-resistant HIV. It also highlights the need for personalized treatment approaches that consider individual patient factors, such as the level of drug resistance and overall health status.

Dr. Camel's Conclusion

Just as a camel endures the harsh desert conditions, individuals living with HIV must navigate the complexities of treatment and drug resistance. This study provides valuable information about the limitations of treatment interruption in drug-resistant HIV, emphasizing the ongoing need for research and personalized care for those impacted by this complex disease.

Date :
  1. Date Completed 2006-11-29
  2. Date Revised 2007-12-03
Further Info :

Pubmed ID

17041858

DOI: Digital Object Identifier

10.1086/508289

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.